Coenzyme Q10 and diabetic endotheliopathy: Oxidative stress and the 'recoupling hypothesis'

QJM: An International Journal of Medicine

Volumn 97, Issue 8, 2004, Pages 537-548

  Chew, G T ^a   Watts, G F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOPHEROL DERIVATIVE; ANTIOXIDANT; ASCORBIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FREE RADICAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ISOPRENALINE; METHACHOLINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXYNITRITE; PRAVASTATIN; RAXOFELAST; SIMVASTATIN; SUPEROXIDE; TETRAHYDROBIOPTERIN; THIOCTIC ACID; UBIDECARENONE; UBIQUINONE; CELL RECEPTOR; DRUG DERIVATIVE; NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANTIOXIDANT ACTIVITY; ARTERY WALL; ARTICLE; ATHEROGENESIS; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTRON TRANSPORT; ENDOTHELIUM CELL; ENDOTHELIUM LESION; HUMAN; HYPOTHESIS; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATION REDUCTION STATE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VITAMIN SUPPLEMENTATION; DIET SUPPLEMENTATION; ENZYMOLOGY; METABOLISM; MITOCHONDRION; PHOSPHORYLATION; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIETARY SUPPLEMENTS; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; HUMANS; MITOCHONDRIA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHOSPHORYLATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; UBIQUINONE;

EID: 7944229937     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hch089     Document Type: Article

References (53)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 2002; 287:2570-81.
2. Katusic ZS. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol 2002; 281:H981-6.
3. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arteriocler Thromb Vasc Biol 2004; 24:413-20.
4. Zafari AM, Harrison DG, Greenling KD. Vascular oxidant stress and nitric oxide bioactivity. From Panza JA, Cannon RO III, eds. Endothelium, Nitric Oxide, and Atherosclerosis. Armonk NY, Futura Publishing, 1999:133-44.
5. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus. Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105:1656-62.
6. Taylor AA. Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. Endocrinol Metab Clin North Am 2001; 30:983-97.
7. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 2003; 52:1-8.
8. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300:1140-2.
9. Watts GF, Playford DA. Dyslipoproteinemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. Atherosclerosis 1998; 141:17-30.
10. Rakugi H, Kamide K, Ogihara T. Vascular signalling pathways in the metabolic syndrome. Curr Hypertens Rep 2002; 4:105-11.
11. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45:623-634.
12. Yusuf S, Dagenais G, Pogne J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Eng J Med 2000; 342:154-60.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:23-33.
14. Chowienczyk PJ, Brett SE, Gopaul NK, et al. Oral treatment with an antioxidant (raxofelast) reduces oxidative stress and improves endothelial function in men with type 2 diabetes. Diabetologia 2000; 43:974-7.
15. Gazis A, White DJ, Page SR, Cockcroft JR. Effect of oral vitamin E (α-tocopherol) supplementation in vascular endothelial function in type 2 diabetes mellitus. Diabet Med 1999; 16:304-11.
16. Ting H, Timimi K, Boles KS, et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin dependent diabetes mellitus. J Clin Invest 1996; 97:22-8.
17. Heitzer T, Finckh B, Albers S, et al. Beneficial effects of α-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001; 31:53-61.
18. Watts GF, Playford DA, Croft KD, et al. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 2002; 45: 420-6.
19. Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q(10) and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003; 168:169-79.
20. Crane FL, Navas P. The diversity of coenzyme Q function. Mol Aspects Med 1997; 18:S1-6.
21. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001; 20:591-8.
22. Mitchell P. The classical mobile carrier function of lipophilic quinones in the osmochemistry of electron-driven proton translocation. In: Lenaz G, Barnabei O, Battino M, eds. Highlights in Ubiquinone Research. London, Taylor and Francis, 1990:77-82.
23. Beyer RF, Ernster L. The antioxidant role of coenzyme Q. In: Lenaz G, Barnabei O, Battino M, eds. Highlights in Ubiquinone Research. London, Taylor and Francis, 1990:191-213.
24. Thomas SR, Neuzil J, Stocker R. Cosupplementation with coenzyme Q prevents the prooxiclant effect of α-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation. Arterioscler Thromb Vasc Biol 1996; 16:687-96.
25. Stocker R, Bowry VW, Frei B: Ubiquinol-10 protects human low-density lipoprotein more efficiently against lipid peroxidation than does α-tocopherol. Proc Natl Acad Sci USA 1991; 88:1646-50.
26. Witting PK, Pettersson K, et al. Anti-atherogenic effect of coenzyme Q10 in apoE knockout mice. Free Radic Biol Med 2000; 29:295-305.
27. Singh RB, Shinde SN, Chopra RK, et al. Effect of coenzyme Q10 on experimental atherosclerosis and chemical composition and quality of atheroma in rabbits. Atherosclerosis 2000; 148:275-82.
28. Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens 1999; 13:203-8.
29. Hodgson JM, Watts GF, Playford DA, et al. Coenzyme Q(10) improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002; 56:1137-42.
30. Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990; 30:596-608.
31. Overvad K, Diamant B, Holm L, et al. Coenzyme Q(10) in health and disease. EurJ Clin Nutr 1999; 53:764-70.
32. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors 1999; 9:273-84.
33. Yokoyama H, Lingle DM, Crestanello J, et al. Coenzyme Q10 protects coronary endothelial function from ischemia reperfusion injury via an antioxidant effect. Surgery 1996; 120:189-96.
34. Lonnrot K, Porsti I, Alho H, et al. Control of arterial tone after long-term coenzyme Q10 supplementation in senescent rats. Br J Pharmacol 1998; 124:1500-6.
35. Raitakari OT, McCredie RJ, Witting P, et al. Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults. Free Radic Biol Med 2000; 28:1100-5.
36. Marx N, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk 2001; 8:203-10.
37. Fruchart JC, Staels B, Duriez P. PPARs, metabolic disease and atherosclerosis. Pharmacol Res 2001; 44:345-52.
38. Barbier O, Pineda Torra I, Duguay C, et al. Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22:717-26.
39. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162:2597-604.
40. Diabetes Atheroscleosis intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357:905-10.
41. Bliznakov EG, Wilkins DJ. Biochemical and clinical consequences of inhibiting coenzyme Q10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): a critical overview. Adv Ther 1998; 15:218-28.
42. van Venrooij FV, van de Ree MA, Bots ML, et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomised, double-blind, placebo controlled trial. Diabetes Care 2002; 25:1211-16.
43. Watts GF, Castelluccio C, Rice-Evans C, et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993; 46:1055-7.
44. Jula A, Marniemi J, Risto H, et al. Effects of diet and simvastatin on serum lipids, insulin and antioxidants in hypercholeserolemic men. A randomised controlled trial. JAMA 2002; 287:598-605.
45. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77:851-4.
46. Satoh K, Yamato A, Nakai T, et al. Effects of 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br J Pharmacol 1995; 116:1894-8.
47. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-16.
48. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-58.
49. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA 1985; 82:901-4.
50. Scheuermann-Freestone M, Madsen PL, Manners D, et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003; 107:3040-6.
51. Diamant M, Lamb HJ, Groeneveld Y, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003; 42:328-35.
52. Steinberg D. Clinical trials of antioxidants in atherosclerosis: are we doing the right thing? Lancet 1995; 346:36-8.
53. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-93.